



Aurobindo Pharma receives second product approval from TGA, Australia for Sertraline Tablets

Aurobindo Pharma Limited is pleased to announce that its wholly owned subsidiary Aurobindo Pharma Australia Pty Ltd has received its second approval from Therapeutic Goods Administration (TGA), Government of Australia for the registration of Sertraline 50mg & 100mg blister pack Tablets containing Sertraline 50mg & 100mg.

The approved indications for these therapeutic products are for treatment of children (aged 6 years and above) and adolescents with obsessive compulsive disorder; major depression, obsessive compulsive disorder and panic disorder in adults and treatment of social phobia (social anxiety disorder) in adults.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries.

For further information, please contact:

Investor Relations

Aurobindo Pharma Limited

Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad

Phone: 040-66725000 / 66725401

Email: ir@aurobindo.com